The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic[…]
Novel Treatments & Drugs
SMART Mesothelioma Procedure Could Extend the Lives of Certain Mesothelioma Patients
Accelerated high dose radiation before surgery created a 65.9 month survival for mesothelioma patients. They were part of a clinical trial in Toronto at the Princess Margaret Cancer Center. The study is named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. There were 96 patients who were treated[…]
The ONCOS-102 Vaccine is Still Showing Promising Results
The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of[…]
New Immuno-Radiology Treatment Being Tested on Mesothelioma
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment[…]
Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]
Quinacrine has Anti-Cancer Effects on Mesothelioma Cells
Pleural mesothelioma is a devastating cancer of the mesothelium, which is a lining of different organs. The most common type of mesothelioma is pleural, which affects the lining of the lungs while the second most common is peritoneal, which surrounds the lining of the abdomen. New treatments are constantly being[…]
Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma
A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding[…]
Opdivo and Yervoy Combination Could Lengthen Aggressive Mesothelioma Sufferers’ Lives
The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising. The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]
A New Study is Looking at the Combination of Keytruda and ONCOS-102
A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but[…]
The Protein Inhibitor Tazemetostat Could Soon Treat Mesothelioma
Mesothelioma could soon be treated by tazemetostat, a new protein inhibitor. Research groups at the American Society of Clinical Oncology made presentations speaking about the effectiveness of the drug on different cancers, with one of them being mesothelioma. It was shown to be effective, and could eventually be a second-line[…]
Skip to content